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Abstract: The term tachycardia-induced cardio-myopathy or tachycardiomyopathy refers to impairment in 
left ventricular function secondary to chronic tachycardia, which is partially or completely reversible once the 
tachyarrhythmia is controlled. Tachycardia-induced cardiomyopathy has been shown to occur both in 
experimental models and in patients with incessant tachyarrhythmia. Data from several studies and from case 
reports have shown that rate control by means of cardioversion, negative chronotropic agents, and surgical or 
catheter-based atrio-ventricular node ablation, resulted in significant improvement of systolic function. The 
diagnosis of tachycardia-induced cardiomyopathy is usually made following observation of marked 
improvement in systolic function after normalization of heart rate. Clinicians should be aware that patients with 
unexplained systolic dysfunction may have tachycardia-induced cardiomyo-pathy, and that controlling the 
arrhythmia may result in improvement of systolic function. 
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Introduction 
Tachycardia-induced cardiomyopathy is caused 
by persistent suprav-entricular or ventricular tachy-
arrhythmia. It is characterized by ventricular 
systolic dysfunction and dilatation and clinical 
manifestation of heart failure that are reversible 
with normalization of heart rate. The concept that 
chronic tachyarrhythmia may lead to reversible 
ventricular dysfunction date back to the early 
1900s [1,2]. Phillips and Levine were first to 
describe the relationship between tachyarrhythmia 
and reversible heart failure in 1949 [3]. 
Tachycardia-induced cardiomyopathy has been 
shown to occur both in experimental models and in 
patients with tachyarrhythmia. Tachycardia-
induced cardiomyopathy may follow any type of 
chronic or frequently recurring paroxysmal 
tachyarrhythm-ias. This review describes the 
pathophysiology and clinical manifestations and 
management of tachycardia-induced 
cardiomyopathy. 
 
Pathophysiology 
Whipple et al. first described experim-ental 
tachycardia-induced cardiomyo-pathy in 1962 [4]. 
They provided the first experimental model for the 
condition; demonstrating that rapid and protracted 
atrial pacing led to low output heart failure. 
Sustained rapid atrial or ventricular pacing in 
experimental models produces a markedly dilated 
cardiomyopathy involving all cardiac chambers 
and severe biventricular systolic and diastolic 
dysfunction [5]. This profound cardiac dilatation is 
typically accompanied by right and left ventricular 
wall thinning, markedly elevated ventricular filling 
pressures and decreased contractile state with 
severe impairment of systolic function. [5-8]. 
Cardiac output is severely reduced, and systemic 
vascular resistance is typically elevated. Moderate 
mitral valve regurgitation may develop late in the 
evolution of heart failure. Mitral valve regurgitation 
is caused by dilatation of the left ventricle and 
stretching of the mitral valve annulus. 
Neurohormonal activation due to low cardiac 
output, results in marked elevations of plasma 
catecholamines, atrial natriuretic peptide, rennin 
and aldosterone levels; further worsening the left 
ventricular function. The precise mechanisms 
responsible for the contractile dysfunction and 
structural changes of pacing-induced 
cardiomyopathy are not fully understood. 
Myocardial energy depletion, impaired energy 
utilization and myocardial ischemia have been 
proposed as possible mechanisms for myocardial 
dysfunction [9,10].  
At the cellular level, the myocyte is the 
elemental component of the heart and is 
responsible for force generation. Translation of 
this force into mechanical pump performance is 
dependent on the relationship between the 
myocyte and extracellular matrix. The extracellular 
matrix ensures proper myocyte alignment during 
diastole, coordinates myocyte contraction during 
systole, and maintains capillary patency 
throughout the cardiac cycle. It has been found 
that chronic supraventricular tachycardia caused 
significant increase in myocyte length, and 
significant disruption of the sarcolemmal-
basement membrane interface [7]. This could 
reduce mechanical pump performance and impair 
ventricular function.  
Abnormal calcium handling may also be 
responsible for tachycardia-induced 
cardiomyopathy. Extensive abnorm-alities in 
calcium channel activity and sarcoplasmic 
reticulum calcium transport may appear as early 
as 24 hours after the initiation of rapid atrial 
pacing, and may persist for up to 4 weeks after 
discontinuation of pacing [11]. The severity of 
calcium cycling abnormalities correlates with the 
degree of ventricular dysfunction. In this manner, 
calcium availability to myocytes may be 
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decreased, with subsequent reduction in 
contractility.  
 
Clinical features and diagnostic considerations 
Tachycardia-induced cardiomyopathy may follow 
any type of chronic or frequently recurring 
paroxysmal tachyarrhythmias. Atrial fibrillation, 
atrial flutter, ectopic atrial tachycardia, 
atrioventricular tachycardia, and ventricular 
tachycardia have all been reported to cause 
tachycardiomyo-pathy. Tachycardia-induced 
cardio-myopathy can occur at any age. It has been 
reported in infants, children [12], adolescents [13], 
and adults [14,15].  
The incidence of tachycardia-induced 
cardiomyopathy is unknown; most reports have 
been small retrospective series or case reports 
involving mostly patients with atrial fibrillation. In 
selected studies of patients with atrial fibrillation, 
approximately 25% to 75% of those with left 
ventricular dysfunction had some degree of 
tachycardia-induced cardiomyopathy [16-20]. 
It is unclear why some patients with chronic 
tachyarrhythmia develop ventricular dysfunction 
whereas others tolerate high rates and maintain 
normal systolic function. Presumed risk factors 
include the type, rate and duration of 
tachyarrhythmia, patient’s age, underlying heart 
disease, drugs, and coexisting medical conditions 
[17]. The diagnosis of tachycardiomyopathy can 
be difficult, and is frequently made in retrospect. 
The diagnosis of tachycardia-related 
cardiomyopathy is made when left ventricular 
systolic function improves to normal or near-
normal level after rate control in patients with 
tachyarrhythmia. 
There are no specific tests or markers available 
to diagnose tachycardia-induced cardiomyopathy. 
A high index of suspicion derived from history and 
clinical features remains the only available tool to 
diagnose this entity. Therefore, the diagnosis of 
tachycardiomyopathy should be considered in any 
patient with left ventricular systolic dysfunction and 
chronic or frequently recurring cardiac arrhythmia. 
Evidence of previously normal systolic function, is 
particularly suggestive of this disorder. The 
ventricular rate that causes tachycardia-induced 
cardiomyopathy has not been determined, 
although any prolonged heart rate greater than 
100 beats per minute may be important. It is 
important to recognize that resting heart rates are 
poor indicators of overall heart rats in patients with 
atrial fibrillation, because the heart rate response 
to exercise may vary. Patients with well-controlled 
resting heart rates may have a rapid ventricular 
response with minimal activity and develop 
tachycardia-induced cardiomyopathy [18,19]. 
Assessment of exercise heart rates and 24-hour 
Holter monitoring may be useful in diagnosing 
tachycardiomyopathy in patients with atrial 
fibrillation and ventricular systolic dysfunction.  
Tachycardia-induced cardiomyopathy should be 
suspected in patients with structural heart disease 
and heart failure who suffer from chronic or 
frequently recurring tachyarrhythmias. A 
tachycardiomyopathy should be always 
considered in patients with Idiopathic” dilated 
cardiomyopathy. Grogan et al. [20] reported 10 
patients with atrial fibrillation and severe LV 
dysfunction, initially believed to have idiopathic 
dilated cardiomyopathy with secondary atrial 
fibrillation. After a mean follow-up of 30 months, 
improvement occurred in all patients after control 
of heart rate with antiarrhythmic drug therapy 
and/or DC cardioversion. Noninvasive imaging 
techniques, such as echocardiography or 
radionuclide ventriculography, usually show left 
and right ventricular dilatation and systolic 
dysfunction. Right ventricular biopsy studies 
revealed nonspecific findings of varying degrees 
of cellular hypertrophy and interstitial fibrosis 
consistent with a nonspecific cardiomyopathy 
[17,21]. 
 
Treatment 
Heart rate normalization, either by rate or 
rhythm control, is the cornerstone of therapy. This 
usually results in increase in ejection fraction, 
reduction in end-systolic and end-diastolic 
volumes and improvement of both symptoms and 
exercise tolerance [16,21-25].  
Regardless of the therapeutic approach used, 
control of the heart rate in patients with chronic 
supraventricular or ventricular tachycardia has 
often resulted in a significant improvement of the 
ventricular function [20,23,24,26,27]. The best 
means to achieve heart rate control vary 
depending on the type of arrhythmia. These may 
include antiarrhythmic drug therapy, external DC 
cardioversion, radiofrequency catheter ablation, 
pacemaker therapy or insertion of an implantable 
cardioverter defibrillator. 
 
Prognosis 
Reduction of ventricular rate, either by 
restoration of sinus rhythm or by slowing the AV 
conduction, is followed by a slow resolution of the 
cardiomyopathy [24]. 
The recovery of ventricular function after 
termination of or control of the tachyarrhythmia is 
extremely variable. Recovery may be complete, 
partial, or totally absent [17,21,24]. The greatest 
improvement in left ventricular function generally 
occurs after 1 month of termination or control of 
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tachyarrhythmia. This is followed by a slower 
improvement that reaches its maximum after 6-
8months [20].  
The gradual time course of recovery of left 
ventricular function after conversion to sinus 
rhythm or heart rate control, resembles the time 
course of recovery of left ventricular dysfunction in 
hibernating myocardium after revascularization 
and may take up to 1 year [17,24,28]. The 
recovery of left ventricular function is substantially 
greater in patients with more profoundly depressed 
left ventricular function at initial evaluation [26]. 
 
Conclusion  
Tachycardiomyopathy is a rare but potentially 
curable form of dilated cardiomyopathy. It should 
be considered in all patients whose systolic 
dysfunction is diagnosed subsequent to or 
concomitant with atrial fibrillation or chronic 
tachyarrhythmia.  
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